Organisation paid for research Program year 2025 Source: CMS Open Payments

Burke Internal Medicine

Neither a doctor nor a teaching hospital

Research payments

$802,375

58 payments

Through program year 2025, Burke Internal Medicine is reported as receiving $802,375 in research payments, across 58 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$301,239	49
2024	Research	$486,706	2
2020	Research	$159	1
2019	Research	$14,271	6

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $784,443 54 payments
Allergan Inc. $9,779 2 payments
Vanda Pharmaceuticals Inc. $7,500 1 payment
Genentech, Inc. $653 1 payment

Studies the money was for Research payments · program years 2019–2025

Phase III efficacy for obesity - without T2DM $276,084 1 payment
phase III efficacy for obesity - with T2DM $210,622 1 payment
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus $157,874 24 payments
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes $135,865 24 payments
A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $8,153 1 payment
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension $7,500 1 payment
safety and efficacy linagliptin vs SU $3,314 2 payments
12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $1,626 1 payment
GLORIA AF Registry Phase II III Core $684 2 payments
Severe Patients Uncontrolled on Ics 2Nd Controller $653 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.